These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
758 related articles for article (PubMed ID: 29382663)
1. Long Noncoding RNA lncSHGL Recruits hnRNPA1 to Suppress Hepatic Gluconeogenesis and Lipogenesis. Wang J; Yang W; Chen Z; Chen J; Meng Y; Feng B; Sun L; Dou L; Li J; Cui Q; Yang J Diabetes; 2018 Apr; 67(4):581-593. PubMed ID: 29382663 [TBL] [Abstract][Full Text] [Related]
2. Hepatic Activation of the FAM3C-HSF1-CaM Pathway Attenuates Hyperglycemia of Obese Diabetic Mice. Chen Z; Ding L; Yang W; Wang J; Chen L; Chang Y; Geng B; Cui Q; Guan Y; Yang J Diabetes; 2017 May; 66(5):1185-1197. PubMed ID: 28246289 [TBL] [Abstract][Full Text] [Related]
3. Long noncoding RNA lncARSR promotes hepatic lipogenesis via Akt/SREBP-1c pathway and contributes to the pathogenesis of nonalcoholic steatohepatitis. Zhang M; Chi X; Qu N; Wang C Biochem Biophys Res Commun; 2018 Apr; 499(1):66-70. PubMed ID: 29555473 [TBL] [Abstract][Full Text] [Related]
4. NFE2 Induces miR-423-5p to Promote Gluconeogenesis and Hyperglycemia by Repressing the Hepatic FAM3A-ATP-Akt Pathway. Yang W; Wang J; Chen Z; Chen J; Meng Y; Chen L; Chang Y; Geng B; Sun L; Dou L; Li J; Guan Y; Cui Q; Yang J Diabetes; 2017 Jul; 66(7):1819-1832. PubMed ID: 28411267 [TBL] [Abstract][Full Text] [Related]
6. FAM3A activates PI3K p110α/Akt signaling to ameliorate hepatic gluconeogenesis and lipogenesis. Wang C; Chi Y; Li J; Miao Y; Li S; Su W; Jia S; Chen Z; Du S; Zhang X; Zhou Y; Wu W; Zhu M; Wang Z; Yang H; Xu G; Wang S; Yang J; Guan Y Hepatology; 2014 May; 59(5):1779-90. PubMed ID: 24806753 [TBL] [Abstract][Full Text] [Related]
7. Hepatic mTORC2 activates glycolysis and lipogenesis through Akt, glucokinase, and SREBP1c. Hagiwara A; Cornu M; Cybulski N; Polak P; Betz C; Trapani F; Terracciano L; Heim MH; Rüegg MA; Hall MN Cell Metab; 2012 May; 15(5):725-38. PubMed ID: 22521878 [TBL] [Abstract][Full Text] [Related]
8. Coordinated regulation of hepatic FoxO1, PGC-1α and SREBP-1c facilitates insulin action and resistance. Sajan MP; Lee MC; Foufelle F; Sajan J; Cleland C; Farese RV Cell Signal; 2018 Mar; 43():62-70. PubMed ID: 29269047 [TBL] [Abstract][Full Text] [Related]
9. Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Li S; Brown MS; Goldstein JL Proc Natl Acad Sci U S A; 2010 Feb; 107(8):3441-6. PubMed ID: 20133650 [TBL] [Abstract][Full Text] [Related]
10. Knockdown of long non-coding RNA Gm10804 suppresses disorders of hepatic glucose and lipid metabolism in diabetes with non-alcoholic fatty liver disease. Li T; Huang X; Yue Z; Meng L; Hu Y Cell Biochem Funct; 2020 Oct; 38(7):839-846. PubMed ID: 32212193 [TBL] [Abstract][Full Text] [Related]
11. Irisin inhibits hepatic gluconeogenesis and increases glycogen synthesis via the PI3K/Akt pathway in type 2 diabetic mice and hepatocytes. Liu TY; Shi CX; Gao R; Sun HJ; Xiong XQ; Ding L; Chen Q; Li YH; Wang JJ; Kang YM; Zhu GQ Clin Sci (Lond); 2015 Nov; 129(10):839-50. PubMed ID: 26201094 [TBL] [Abstract][Full Text] [Related]
12. Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis. Kim K; Ryu D; Dongiovanni P; Ozcan L; Nayak S; Ueberheide B; Valenti L; Auwerx J; Pajvani UB Gastroenterology; 2017 Dec; 153(6):1568-1580.e10. PubMed ID: 28859855 [TBL] [Abstract][Full Text] [Related]
13. Hepatocyte-secreted FAM3D ameliorates hepatic steatosis by activating FPR1-hnRNP U-GR-SCAD pathway to enhance lipid oxidation. Hu Y; Li J; Li X; Wang D; Xiang R; Liu W; Hou S; Zhao Q; Yu X; Xu M; Zhao D; Li T; Chi Y; Yang J Metabolism; 2023 Sep; 146():155661. PubMed ID: 37454871 [TBL] [Abstract][Full Text] [Related]
14. The adipokine sFRP4 induces insulin resistance and lipogenesis in the liver. Hörbelt T; Knebel B; Fahlbusch P; Barbosa D; de Wiza DH; Van de Velde F; Van Nieuwenhove Y; Lapauw B; Thoresen GH; Al-Hasani H; Müller-Wieland D; Ouwens DM; Kotzka J Biochim Biophys Acta Mol Basis Dis; 2019 Oct; 1865(10):2671-2684. PubMed ID: 31336149 [TBL] [Abstract][Full Text] [Related]
15. Tangshen formula attenuates hepatic steatosis by inhibiting hepatic lipogenesis and augmenting fatty acid oxidation in db/db mice. Kong Q; Zhang H; Zhao T; Zhang W; Yan M; Dong X; Li P Int J Mol Med; 2016 Dec; 38(6):1715-1726. PubMed ID: 27840945 [TBL] [Abstract][Full Text] [Related]
16. Lipid accumulation stimulates the cap-independent translation of SREBP-1a mRNA by promoting hnRNP A1 binding to its 5'-UTR in a cellular model of hepatic steatosis. Siculella L; Tocci R; Rochira A; Testini M; Gnoni A; Damiano F Biochim Biophys Acta; 2016 May; 1861(5):471-81. PubMed ID: 26869449 [TBL] [Abstract][Full Text] [Related]
17. MicroRNA-206 prevents hepatosteatosis and hyperglycemia by facilitating insulin signaling and impairing lipogenesis. Wu H; Zhang T; Pan F; Steer CJ; Li Z; Chen X; Song G J Hepatol; 2017 Apr; 66(4):816-824. PubMed ID: 28025059 [TBL] [Abstract][Full Text] [Related]
18. Ellagic acid ameliorates AKT-driven hepatic steatosis in mice by suppressing de novo lipogenesis via the AKT/SREBP-1/FASN pathway. Zhang C; Hu J; Sheng L; Yuan M; Wu Y; Chen L; Wang G; Qiu Z Food Funct; 2019 Jun; 10(6):3410-3420. PubMed ID: 31123744 [TBL] [Abstract][Full Text] [Related]
19. Hepatic mTOR-AKT2-Insig2 signaling pathway contributes to the improvement of hepatic steatosis after Roux-en-Y Gastric Bypass in mice. Pan Q; Qin T; Gao Y; Li S; Li D; Peng M; Zhai H; Xu G Biochim Biophys Acta Mol Basis Dis; 2019 Mar; 1865(3):525-534. PubMed ID: 30562559 [TBL] [Abstract][Full Text] [Related]
20. Ursodeoxycholic acid ameliorates hepatic lipid metabolism in LO2 cells by regulating the AKT/mTOR/SREBP-1 signaling pathway. Hu J; Hong W; Yao KN; Zhu XH; Chen ZY; Ye L World J Gastroenterol; 2019 Mar; 25(12):1492-1501. PubMed ID: 30948912 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]